Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges .

Development 52

Development In-Vivo Compound Screening Clinical Development 52

Drug Discovery World

FEBRUARY 22, 2024

Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Libra’s pipeline targets mechanisms that can mitigate protein pathology associated with CNS degenerative disorders.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vivo 52

Drug Discovery World

JANUARY 23, 2023

Clinical trials revealed eight out of nine predictions were correct. We witnessed the unprecedented pace of vaccine development, fuelled by cutting-edge mRNA technology. Today, there have been efficacy readouts from large randomised controlled clinical trials for nine of our predictions – eight of which we predicted correctly.

Drugs 59

Drugs Clinical Trials Clinical Trials Compound Screening 59

Drug Discovery World

AUGUST 15, 2023

Although such electrophysiological systems may be more predictive of potential cardiac safety and efficacy than non-functional binding assays, many apparently attractive new drugs are still being discontinued later in development. Unexpected late-stage failures in drug development are, of course, the costliest.

Drugs 52

Drugs In-Vivo Development Research 52